A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors.

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 25, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2024

Conditions

Advanced Solid Tumor

Interventions

BIOLOGICAL

EMB-09

EMB-09 is a FIT-Ig® bispecific antibody against PD-L1 and OX40.

Trial Locations (4)

RECRUITING

Peninsula and South Eastern Haematology & Oncology Group, Frankston

RECRUITING

GenesisCareNorthShore, Leonards Hill

RECRUITING

Blacktown Hospital, Sydney

RECRUITING

FUSCC, Shanghai

All Listed Sponsors

lead

Shanghai EpimAb Biotherapeutics Co., Ltd.

INDUSTRY

NCT05263180 - A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. | Biotech Hunter | Biotech Hunter